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a  b  s  t  r  a  c  t
To  consolidate  the  integration  of  the  fragmented  European  vaccine  development  landscape,  TRANSVAC
–  the  European  Network  of  Vaccine  Research  and  Development,  funded  by the  European  Commission
(EC)  – has initiated  the  development  of a roadmap  through  a process  of stakeholder  consultation.  The
outcome  of  this  consultation  highlighted  the  need  for transnational  cooperation  and  the  opportunities
that  could  be generated  by such  efforts.  This cooperation  can  be  achieved  through  the  establishment
of  a European  Vaccine  Research  and  Development  Infrastructure  (EVRI).  EVRI  will  support  cooperation
between  existing  vaccine  Research  and  Development  (R&D)  organisations  from  the  public  and  private
sector  and  other  networks  throughout  Europe.  It will become  sustainable  over time  by receiving  support
from  multiple  sources  including  the  EC,  European  Union  (EU)  Member  States,  European  vaccine  compa-
nies,  EVRI  partner  organisations,  and  by income  generated.  Different  stakeholders  have  demonstrated
support  for  the  concept  of a  vaccine  infrastructure  and  agree  that such  an  infrastructure  can function  as
leverage  institution  between  public  and  private  institutions  thus  making  signiﬁcant  contributions  to the
vaccine  ﬁeld  as  a whole  in its quest  to  develop  vaccines.
EVRI  will  be launched  in  three  phases:  preparatory  (during  which  the  legal  and administrative  frame-
work  will  be deﬁned  and  a business  plan  will  be elaborated),  implementation  and  operational.  If  sufﬁcient
political  and  ﬁnancial  commitment  can  be  secured  from  relevant  national  and  European  entities  as
well  as  from  the  private  sector  and  other  stakeholders,  it could  enter  into  operational  phase  from  2017
onwards.  In conclusion,  EVRI  can  make  vaccine  R&D  more  efﬁcient  and  help  address  European  and  global
health challenges,  help  alleviate  the  burden  and  spread  of  infectious  diseases,  thus  contributing  to the
sustainability  of  public  healthcare  systems.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Background
Children in all countries are routinely immunised against major
iseases, and vaccination has become central to global public health
fforts [1]. The impact of vaccines can be measured not just in
erms of public health, but also in economic terms: reducing the
ost of healthcare, decreasing lost labour force productivity and
ontributing to social and economic development.
In March 2000, the European Council of Lisbon set as a strate-
ic goal that Europe become the ‘most competitive and dynamic
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knowledge-based economy in the world’ by 2010. To achieve this
objective, it created the European Research Area that contributes
to strengthen the scientiﬁc and technological bases of the EU and
its Member States, their competitiveness and their capacity to col-
lectively address major scientiﬁc challenges. With over 15% of its
revenues invested in R&D and over 20,000 employees in Europe,
the vaccine industry is a major contributor to the knowledge-based
economy [2]. Europe’s leading position in vaccines is, however,
increasingly threatened by North America and BRIC (Brazil, Rus-
sia, India and China) countries [3], as evidenced for example by
the decrease in the proportion of R&D projects located in Europe
(down from 71% in 2006, through 58% in 2008, to 50% in 2010) [4],
especially for R&D projects involving new antigens.
European scientists are leading many initiatives in vaccine
design and development. While there are many vaccine candidates
especially in early stages of the development process, translation
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f these candidates from discovery research through to preclinical
nd clinical development has turned out to be a major bottleneck.
everal difﬁculties within this “translation gap” directly impact on
accine development; these include for example the lack of access
o innovative technologies or lack of ﬁnancial support to acquire
uch novel technologies, lack of access to relevant expertise, and
he lengthy regulatory authorisation process for the approval of
ew products. Vaccine development is a lengthy and iterative pro-
ess requiring signiﬁcant resources and expertise, and it can take
ver 10 years to bring a vaccine to market.
Translational research – taking ideas from the bench into clinical
rials – is not attractive to scientists working in the public sector: it
resents high risks of failure, has to comply with regulatory require-
ents, and is underrated for the development of a research career.
any programmes have been initiated in the United States (US)
nd the EU to foster and secure pipeline management and product
evelopment [3]. Although very welcome, these initiatives often
ave been limited: the organisations eligible to apply for fund-
ng are limited and funding usually does not exceed ﬁve years. In
urope, for example, projects are usually funded for periods ran-
ing from three to ﬁve years, and possibilities to renew successful
nitiatives very frequently do not exist. A recent analysis of R&D
atent and publication networks over 10 years suggests that the
ision announced for a European Research Area has not yet been
elivered and that Europe remains a collection of national innova-
ion systems with cross-border collaboration below expectation for
n integrated European Research Area [5]. This failure also affects
he vaccine research area and warrants redress.
Research infrastructures play an increasingly important role in
dvancing research and innovation and in shaping and integrating
cientiﬁc communities across borders. These infrastructures can be
eﬁned as facilities, resources, systems and related services that
re used by research communities to conduct research and foster
nnovation in their respective ﬁelds [6]. TRANSVAC – the European
etwork of Vaccine Research and Development – is a collaborative
nfrastructure project funded under the EC’s 7th Framework Pro-
ramme  for Research and Technological Development. The mission
f TRANSVAC (www.transvac.org) – which brought together 14
artner organisations and ﬁve interested parties from seven dif-
erent EU Member States – was to integrate capacities existing in
ifferent EU Member States with the aim to support European net-
orking and transnational access to vaccine development facilities
nd/or related services, and to improve the services provided by
hese infrastructures through joint research activities (a summary
f the services provided and research conducted by TRANSVAC will
e reported elsewhere; under preparation).
In order to address the translational gap and other issues
mpacting on vaccine R&D, TRANSVAC set out to identify currently
xisting major bottlenecks and barriers in translational vaccine
evelopment, based on a bottom-up stakeholder consultation pro-
ess. The objective of the ﬁrst stakeholder meeting held in October
010 was to deﬁne how best to support, improve and accelerate
accine R&D in Europe [7]. In a series of subsequent workshops
onducted in 2011 and 2012, TRANSVAC stakeholders analysed
he needs previously identiﬁed and discussed how they could be
ddressed through a pan-European collaborative effort. Their con-
lusions were translated into a draft proposal for the establishment
f a European vaccine R&D infrastructure, which was  submitted end
f 2013 for comments and validation to a wider group of stake-
olders. A detailed questionnaire that was part of the consultation
rocess led to the identiﬁcation of priority areas for EVRI. Finally, an
dvanced draft of the TRANSVAC Roadmap was publicly presented
nd discussed during a ﬁnal stakeholder workshop in Brussels in
une 2013 (see Ref. [7] for further information about agendas and
articipants in all workshops organised during TRANSVAC). This
onsultation process culminated in the preparation of a roadmap (2014) 7021–7024
for the establishment of a EVRI [7] which is brieﬂy outlined in this
article. The roadmap will serve as a blueprint for the development
of a sustainable infrastructure for vaccine R&D in Europe and will
serve as a reference document to inform national and European
policy makers and funding bodies.
2. EVRI – European Vaccine R&D Infrastructure
EVRI strives to be a pan-European infrastructure that can accel-
erate product development and at the same time reduce costs
through the optimal use of existing national research capacities.
It will build on existing networks, capacities and platforms such
as those developed by TRANSVAC and others and will provide a
full range of services to further test and advance the development
of vaccines candidates. EVRI’s activities will address the various
phases of pre-competitive vaccine development: basic research,
discovery, pre-clinical and early clinical research, as well as sup-
porting tools, technology and expertise, including bioinformatics.
Both human and veterinary vaccines will be within the scope of
EVRI, including prophylactic as well as therapeutic vaccines for
disease targets in humans.
EVRI will facilitate the development of vaccine candidates from
proof-of-concept in animals to proof-of-concept in humans and
contribute to bridging the recognised translational gap between
preclinical and clinical research. Further clinical evaluation and
vaccine commercialisation will require links to other networks and
industrial partners. In addition to the various scientiﬁc disciplines
related to vaccinology (e.g. microbiology, immunology etc.), EVRI
will address other areas such as ethics, epidemiology, pharmaco-
economy, public policy, sociology and regulatory science.
More speciﬁcally, EVRI has as objectives to:
• Provide a full range of vaccine R&D services.
• Improve the services provided by conducting internal research.
• Conduct regulatory science by functioning as a reference vaccine
research platform for the European Medicines Agency (EMA).
• Reinforce education in multidisciplinary vaccinology.
2.1. Vaccine R&D services
EVRI will link and align human and ﬁnancial resources and
drive long-term co-operations between research programmes
with shared objectives. It will help Europe create platforms and
networks of excellence to overcome and avoid duplication and to
improve efﬁcacy and effectiveness of research efforts throughout
Europe by providing access to services including, but not limited
to:
• Tools and platforms relevant for vaccine research, e.g. bioinfor-
matics, in vivo imaging technologies, microarrays and systems
vaccinology.
• Animal models (e.g. mice, ferrets, non-human primates, pigs) and
platforms for pre-clinical safety and immunogenicity studies in
animal models.
• Immunological assays/identiﬁcation of correlates of protec-
tion/identiﬁcation of biological markers of diseases and protec-
tion/identiﬁcation of efﬁcacy criteria and endpoints.
• Early clinical trial expertise and infrastructures to optimise trans-
lation from animal models to humans.
• Advanced, GMP-compatible, expression systems (yeast, bacterial,
mammalian cells, recombinant vectors).
• Vaccine formulation services, including characterisation and
analysis of ﬂuid, adsorbed and dry formulations, adjuva-
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platforms for antigen/nucleic acid delivery, and stabilisation
techniques.
GMP manufacturing platforms (e.g. peptide, bacterial, viral vec-
tor).
Good Manufacturing Practice (GMP) production for pre-licensure
clinical trials.
Vaccine-speciﬁc project management and expert technical
and/or scientiﬁc advice on a consultancy basis, including con-
struction of an Investigational Medicinal Product Dossier (IMPD)
and product lifecycle management.
Project management consulting/product and clinical develop-
ment advice and support.
These services could be made available by the service provider
remote service provision) or through an ‘open-lab’ approach. This
open-lab’ would offer the dual advantage of being cost-efﬁcient as
ell as a source of new knowledge for the researcher.
Vaccine R&D infrastructures are highly specialised, requiring
utting-edge competencies and advanced technologies. The critical
ass, and resulting capacity building, can only be obtained through
etworking and international collaboration between leading stake-
olders rather than through the multiplication of infrastructures at
ational level.
Projects conducted at EVRI will be selected according to deﬁned
riteria, including their relevance to strategic planning of European
accine research, their excellence and their potential. Improving
nd harmonising selection thanks to a better deﬁnition of selec-
ion criteria will reduce the number of ‘bad bets’ and increase cost
fﬁciency of the entire vaccine development process.
.2. Joint research activities
EVRI will also conduct a critical amount of joint internal research
ctivities, which will improve the quality of the integrated ser-
ices provided. EVRI will explore and develop new technologies
nd techniques, which will underpin the efﬁcient use of the infra-
tructure.
Joint research will include the following areas:
Development of animal models.
Optimisation of translation from animal models to humans.
Development of systems vaccinology and identiﬁcation of
biomarkers and correlates of protection.
Development of a scientiﬁc and ethical framework for human
challenge studies.
Harmonisation and standardisation of assays.
.3. Regulatory science vaccine research platform for EMA
Regulatory approval for new vaccines is often complex, time
onsuming and costly. Although general guidelines exist (e.g. from
he World Health Organization [WHO] and EMA  [8,9]), they may
ave to be adapted according to the speciﬁcity of each vaccine.
n the US, ‘Investigational New Drug’ (IND) submission is a major
ilestone in the vaccine development process. Before starting clini-
al trials, vaccine developers must submit pre-clinical data and the
genda for future clinical trials of their IND to the US Food and
rug Administration (FDA). The information requested is intended
o put the product development plan into perspective so that
he US FDA can anticipate the needs of the vaccine developer. In
urope, regulatory permission to conduct a clinical trial, including
uthorisation from relevant independent ethics committees and/or
nstitutional review boards, must be obtained from the compe-
ent authorities of the EU Member State where the clinical trial
s being performed. This authorisation, however, is not to be con-
idered as scientiﬁc advice on the development programme of the (2014) 7021–7024 7023
Investigational Medicinal Product (IMP) that is being tested. Sci-
entiﬁc advice can be obtained independently, on a voluntary and,
with some exceptions, on a fee-for-service basis from EMA  and/or
from National Regulatory Agencies. In the absence of such advice,
it is possible that EMA  may  consider that the trial design, assays,
biomarkers, endpoints or comparators are neither relevant nor suf-
ﬁcient to register the product. Regulatory agencies such as EMA, US
FDA and international organisations such as WHO  base their guide-
lines/evaluation criteria on the scientiﬁc evidence obtained by their
own services or from external expert groups. EMA, for instance,
relies mainly on data provided by external research groups. With
the aim to provide EMA  with the scientiﬁc evidence it needs to
address issues impacting the licensure of new and improved vac-
cines, EVRI will establish expert groups to address emerging issues
regarding regulatory approval of vaccines such as assay validation,
standardisation and harmonisation; validation of biomarkers and
endpoints for clinical trials; reference animal models; comparative
studies. It will also be the link between those groups and EMA. Dur-
ing the preparation and implementation stages, discussions with
EMA  will be conducted in order to specify the needs and deﬁne the
services to be provided by EVRI.
2.4. Reinforce education in vaccinology
Vaccinology is multidisciplinary and multi-professional by
nature. It covers basic research in immunology and microbiology at
one end of the vaccine development process, translational research
and product development in the middle, and logistics, clinical deliv-
ery and public health education at the other end. Some aspects
of vaccinology are included in various curricula: medicine, bio-
logical sciences, pharmaceutical sciences, nursing, midwifery, and
biotechnology. Given the huge impact of vaccinology on global
health, it merits recognition as a discipline in its own  right. EVRI
will drive Europe’s capacity in vaccinology through education and
training. Modular programmes will meet educational objectives for
the spectrum of vaccinology deliverables. EVRI advanced courses,
with a strong hands-on component, will link the best institutions
in Europe. EVRI partner institutions will deliver speciﬁc training
courses focusing on different aspects of vaccinology, which will be
validated by a system of credits.
Theoretical training should go hand-in-hand with practical
training through internships in the vaccine formulation and man-
ufacturing sites of EVRI or its corporate partners. The portfolio
content will be adjusted according to participants’ and faculty’s
feedback and on the needs expressed by the vaccine community.
The development and implementation of education and training
in vaccinology by EVRI will also involve academic research organi-
sations from different EU Member States which will facilitate the
accreditation throughout Europe of the training offered.
2.5. EVRI – partners and users
EVRI will be accessible to the entire European vaccine devel-
opment community. Partners and users will include (i) academic
public sector, and non-proﬁt organisations, (ii) small and medium
sized enterprises, (iii) product development partnerships, (iv) vac-
cine pharmaceutical industry, (v) regulatory agencies, and (vi)
patients’ organisations. As EVRI must be sustainable, services will
generally be offered on a fee-for-service basis. The fee for academic
research groups and non-proﬁt organisations will cover operational
costs, while corporate fees will include a proﬁt margin. In addition,
to ensure potential access to services at no cost, EVRI will make
open calls for awards for research and training. These will support
projects distinguished by their excellence and high potential. EVRI
will ask for a discretionary funding element to support such awards
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EVRI will work with partners to establish guidelines for Intel-
ectual Property (IP) rights related to research ﬁndings facilitated
y EVRI. These guidelines will recognise institutional background
P, promote fair ownership of IP rights, the use and dissemination
f IP, access rights and conﬁdentiality.
Different rules may  apply depending on the nature and degree
f EVRI’s contribution to the development and funding of a spe-
iﬁc project. An IP agreement will be signed before collaboration
egins and the project will be designed to include a case-by-case
valuation. In general, IP generated by EVRI’s services will remain
he ownership of the user whereas IP generated by EVRI member
rganisations during joint research activities will be shared fairly
mong the different contributors.
.6. Structure of EVRI
EVRI will be a de-centralised organisation under a coordinating
ecretariat, associating leading vaccine R&D institutions in both
uman and veterinary vaccines ﬁelds, and integrating activities
hat currently exist in different EU Member States and Associated
ountries. In addition to the Secretariat, an Executive Committee,
oordinators of different thematic areas, an independent Scien-
iﬁc Advisory Committee, and an Independent Ethics Committee
re foreseen to form part of the EVRI’s governance structure.
RANSVAC has already established close links with other rele-
ant and currently existing European research infrastructures such
s the European Clinical Research Infrastructure Network (ECRIN)
nd the European Advanced Translational Research Infrastructure
n Medicine (EATRIS). Synergies with these and other infrastruc-
ures will be duly exploited by EVRI and discussions have been
nitiated regarding which strategy to follow to ensure maximum
oordination and integration with existing infrastructures existing
n Europe.
. Next steps towards establishment
EVRI is foreseen to be established in three different phases. The
reparatory phase corresponds to the development and ﬁnalisation
f the legal, ﬁnancial and organisational structures of EVRI, which
ill include, amongst others, the preparation of policies for dealing
ith conﬁdentiality and IP issues and for the establishment of poli-
ies to avoid unfair competition with organisations from the private
ector that may  offer commercial scientiﬁc-technical services sim-
lar to those to be offered by EVRI. During the preparatory phase
lso a feasibility study and a business plan will be prepared as part
f this phase which will be followed by the implementation phase
uring which additional funding will be secured to enable the for-
al  launch of EVRI, the ﬁrst technical and networking activities will
e set up, and plans for educational and training programmes will
e rolled out in addition to other business development activities.
inally, EVRI will enter its operational phase, with the objective of
ecoming ﬁnancially sustainable within ﬁve years. To achieve this,
upport from multiple sources must be translated into long-term
nancial commitments.
EVRI’s viability will depend on its ﬁnancial sustainability as well
s on its public health and socio-economic impact in the medium
nd long-term. Multiple sources of funding will be tapped to sup-
ort the different activities undertaken by EVRI, including the EC
nd participating EU Member States, income from fees and royalties
nd, potentially, contributions from the private sector. Monitoring
VRI’s activities and their impact, using the feedback from members
nd users, will contribute to improving them and adjusting them to
he changing or emerging needs of European vaccine developers.
[
[ (2014) 7021–7024
Both internal and external factors impacting the sustainability of
EVRI will be taken into consideration. The sustained leadership of
Europe in the vaccine ﬁeld, an important effect of EVRI’s activities,
will ensure continued enthusiasm as well as renewed support for
EVRI from stakeholders in both public and private sectors.
4. Conclusions
As described in the roadmap and summarised in this article, the
European Vaccine R&D Infrastructure – EVRI – will foster innova-
tion for both prophylactic and therapeutic vaccines. It will address
European and global health challenges, and thereby promote socio-
economic development in Europe. EVRI will directly and indirectly
contribute to the development of novel vaccines against diseases
that are currently non-preventable and against pathogens that have
become resistant to antibiotics, and will support the development
of improved next-generation vaccines. EVRI will play a major role in
the health and well-being of European citizens and the global pop-
ulation. By fostering the European vaccine R&D, it will strengthen
the competitiveness of the European vaccine industry, a key con-
tributor to the creation of wealth and employment in Europe.
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